Novel outpatient infusion model of blinatumomab: case studies of two patients
10.13303/j.cjbt.issn.1004-549x.2025.04.015
- VernacularTitle:2例贝林妥欧单抗输注新模式的报告
- Author:
Guijun LI
1
;
Xuemei JIANG
1
;
Xin WANG
1
;
Qiuxia XU
1
;
Jianhui LI
1
;
Susi DAI
1
;
Ying HE
1
;
Hai YI
1
;
Dan CHEN
1
Author Information
1. Department of Hematology, General Hospital of Western Theater Command of the Chinese People's Liberation Army, Chengdu 610000, China
- Publication Type:Journal Article
- Keywords:
blinatumomab;
acute lymphoblastic leukemia (ALL);
outpatient infusion
- From:
Chinese Journal of Blood Transfusion
2025;38(4):557-561
- CountryChina
- Language:Chinese
-
Abstract:
[Objective] To evaluate the feasibility of a novel outpatient infusion model for blinatumomab in two acute lymphoblastic leukemia (ALL) patients, aiming to address challenges of poor treatment tolerance, high healthcare costs, and compromised quality of life, thereby providing clinical insights for broader adoption of this approach. [Methods] Two post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients undergoing blinatumomab maintenance therapy were selected to evaluate the efficacy of the outpatient infusion model. Patient selection criteria, nursing protocols, standardized workflows, and advancements in infusion practices were systematically analyzed combined with a review of global developments in this field. [Results] Both patients completed outpatient blinatumomab infusion without severe adverse events, demonstrating preliminary feasibility and safety of this model. The novel approach enhanced treatment convenience, reduced hospitalization costs, and improved quality of life. [Conclusion] Despite the limited sample size, this pilot study highlights the potential of outpatient blinatumomab administration as a viable alternative to traditional inpatient regimens.
